vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $13.8M, roughly 1.3× CB Financial Services, Inc.). On growth, CB Financial Services, Inc. posted the faster year-over-year revenue change (19.9% vs -25.7%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $-15.8M). Over the past eight quarters, CB Financial Services, Inc.'s revenue compounded faster (1.2% CAGR vs -15.9%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CBFV vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $18.7M |
| Net Profit | — | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | 38.1% | -6.9% |
| Net Margin | — | -0.8% |
| Revenue YoY | 19.9% | -25.7% |
| Net Profit YoY | — | 97.6% |
| EPS (diluted) | $0.90 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $13.5M | $18.7M | ||
| Q1 25 | $12.1M | $50.9M | ||
| Q4 24 | $13.2M | $38.1M | ||
| Q3 24 | $12.7M | $33.4M | ||
| Q2 24 | $12.2M | $25.1M | ||
| Q1 24 | $13.5M | $41.5M |
| Q4 25 | — | — | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $3.9M | $-154.0K | ||
| Q1 25 | $1.9M | $23.5M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | $3.2M | $5.7M | ||
| Q2 24 | $2.6M | $-6.5M | ||
| Q1 24 | $4.2M | $13.8M |
| Q4 25 | 38.1% | — | ||
| Q3 25 | -289.8% | — | ||
| Q2 25 | 35.0% | -6.9% | ||
| Q1 25 | 19.3% | 44.4% | ||
| Q4 24 | 23.1% | 46.4% | ||
| Q3 24 | 31.2% | 12.3% | ||
| Q2 24 | 26.4% | -33.7% | ||
| Q1 24 | 37.9% | 28.1% |
| Q4 25 | — | — | ||
| Q3 25 | -235.2% | — | ||
| Q2 25 | 29.3% | -0.8% | ||
| Q1 25 | 15.8% | 46.2% | ||
| Q4 24 | — | 49.6% | ||
| Q3 24 | 25.3% | 17.2% | ||
| Q2 24 | 21.8% | -26.0% | ||
| Q1 24 | 31.1% | 33.3% |
| Q4 25 | $0.90 | — | ||
| Q3 25 | $-1.07 | — | ||
| Q2 25 | $0.74 | — | ||
| Q1 25 | $0.35 | — | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.60 | — | ||
| Q2 24 | $0.51 | — | ||
| Q1 24 | $0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $157.5M | $119.9M |
| Total Assets | $1.5B | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | — | ||
| Q3 25 | $55.9M | — | ||
| Q2 25 | $64.5M | $49.0M | ||
| Q1 25 | $61.3M | $47.6M | ||
| Q4 24 | $49.6M | $38.1M | ||
| Q3 24 | $147.3M | $40.6M | ||
| Q2 24 | $142.6M | $43.2M | ||
| Q1 24 | $73.7M | $36.2M |
| Q4 25 | $157.5M | — | ||
| Q3 25 | $152.5M | — | ||
| Q2 25 | $148.4M | $119.9M | ||
| Q1 25 | $148.3M | $25.0M | ||
| Q4 24 | $147.4M | $-456.0K | ||
| Q3 24 | $149.1M | $-23.5M | ||
| Q2 24 | $142.9M | $-31.2M | ||
| Q1 24 | $141.6M | $-31.7M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | $175.1M | ||
| Q1 25 | $1.5B | $98.5M | ||
| Q4 24 | $1.5B | $120.5M | ||
| Q3 24 | $1.6B | $139.0M | ||
| Q2 24 | $1.6B | $159.2M | ||
| Q1 24 | $1.5B | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $-15.8M |
| Free Cash FlowOCF − Capex | $17.2M | $-15.8M |
| FCF MarginFCF / Revenue | 124.1% | -84.6% |
| Capex IntensityCapex / Revenue | 4.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | — | ||
| Q3 25 | $4.6M | — | ||
| Q2 25 | $4.1M | $-15.8M | ||
| Q1 25 | $4.0M | $-21.0M | ||
| Q4 24 | $6.8M | $-19.9M | ||
| Q3 24 | $3.1M | $-20.7M | ||
| Q2 24 | $-1.2M | $-19.5M | ||
| Q1 24 | $3.3M | $-26.0M |
| Q4 25 | $17.2M | — | ||
| Q3 25 | $4.5M | — | ||
| Q2 25 | $3.9M | $-15.8M | ||
| Q1 25 | $3.9M | $-21.2M | ||
| Q4 24 | $3.4M | $-20.0M | ||
| Q3 24 | $2.2M | $-20.7M | ||
| Q2 24 | $-2.4M | $-19.6M | ||
| Q1 24 | $2.3M | $-26.2M |
| Q4 25 | 124.1% | — | ||
| Q3 25 | 186.5% | — | ||
| Q2 25 | 28.8% | -84.6% | ||
| Q1 25 | 32.5% | -41.6% | ||
| Q4 24 | 26.0% | -52.5% | ||
| Q3 24 | 17.4% | -62.1% | ||
| Q2 24 | -19.6% | -78.2% | ||
| Q1 24 | 17.0% | -63.1% |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 1.9% | 0.1% | ||
| Q1 25 | 0.8% | 0.2% | ||
| Q4 24 | 25.1% | 0.2% | ||
| Q3 24 | 6.7% | 0.1% | ||
| Q2 24 | 10.0% | 0.4% | ||
| Q1 24 | 7.2% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | 0.95× | -3.61× | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBFV
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
